MeiraGTx

1 month ago · globenewswire.com

LONDON and NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the appointment of Alan M. Sebulsky to its Board of Directors.

2 months ago · gurufocus.com

Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in S

3 months ago · zacks.com

MeiraGTx Holdings PLC (MGTX) came out with quarterly earnings of $1.71 per share, beating the Zacks Consensus Estimate of a loss of $0.39 per share. This compares to a loss of $0.48 per share a year ago.

3 months ago · globenewswire.com

Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe grade 2/3 radiation-induced xerostomia   Completed the acquisition of all interests and rights to botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP) from Johnson & Johnson* (J&J) for $25 million   Strengthened balance sheet with $100 million equity financing concurrent with the bota-vec acquisition   Secured up to $400 million strategic investment from Oberland Capital, with up to $375 million in non-dilutive capital to support development and commercialization of AAV2-hAQP1 and bota-vec   Anticipate submission of global regulatory filings for approval of bota-vec in 2026 and potential BLA filing for AAV2-hAQP1 in mid-2027              LONDON and NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the second quarter ended June 30, 2026, and provided a corporate update. “During the second quarter of 2026, we made tremendous progress towards transforming MeiraGTx into a commercial company,” said Alexandria Forbes, Ph.D.

3 months ago · prnewswire.com

Graviton received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for a novel capsule formulation of GV101 on August 7, 2026. FDA clearance marks a critical regulatory milestone in advancing this formulation of GV101, a capsule with improved PK and oral availability, into human trials for Friedreich's ataxia (FA).

3 months ago · globenewswire.com

LONDON and NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the Compensation Committee of the Company's Board of Directors approved equity awards under the Company's 2026 Employment Inducement Award Plan to a new employee. The equity awards were granted as an inducement material to the new employee entering employment with MeiraGTx in accordance with Nasdaq Listing Rule 5635(c)(4).

3 months ago · seekingalpha.com

MeiraGTx Holdings plc is positioned potentially for significant upside with late-stage gene therapy assets targeting large, high-unmet-need indications. AAV2-hAQP1 for radiation-induced xerostomia could address a $3.7B peak sales market with no direct competition; pivotal Phase 2 data expected 2Q27. Robust optionality from GAD for Parkinson's, bota-vec for XLRP, milestone payments, and the innovative Riboswitch platform enhances MGTX's valuation case.

4 months ago · zacks.com

The mean of analysts' price targets for MeiraGTx (MGTX) points to a 128.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

4 months ago · fool.com

Stuart Naylor liquidated 27,659 shares for $409,000 on July 7, 2026, at a weighted average price of $14.80 per share. The transaction resulted in a 4% reduction of the insider's total direct equity holdings in the company.

4 months ago · zacks.com

MeiraGTx (MGTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.